GeneDx (WGS) AGM 2026 summary

Opening remarks and agenda

• The meeting was held virtually to increase inclusivity and reach more stockholders.

• Board members and officers present were introduced, including the CEO, CFO, and Chief Legal Officer.

• The agenda included a business review and four formal proposals for stockholder voting.

Financial performance review

• Reported $427.5 million in revenue for 2025, representing 41% year-over-year growth.

• Achieved a 71% adjusted gross margin and $41.8 million in adjusted net income.

• Received FDA Breakthrough Device designation for ExomeDx and GenomeDx tests.

Strategic initiatives and plans

• Focused on expanding exome and genome testing utilization and optimizing unit economics.

• Actively growing the core geneticist and pediatric specialist base and entering new markets.

• Leveraging the SAVES-Kids study to demonstrate cost savings and strengthen payer relationships.

• Exploring future opportunities in biopharma and data partnerships using the GeneDx Infinity platform.